- Larger facility will significantly increase Ionis'
development chemistry and manufacturing capabilities
- Sudberry Properties will build the facility and lease to
Ionis for 20-plus years; Ionis retains option to renew and right of
first offer to purchase the property
CARLSBAD, Calif., Oct. 12,
2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(Nasdaq: IONS) today announced that it has entered into an
agreement with Sudberry Properties to develop and lease a new
development chemistry and manufacturing site in Oceanside, Calif. Sudberry will develop and
construct the shell for the approximately 217,000-square-foot
building. Ionis will design and construct improvements to customize
the facility. Under the terms of the agreement, Ionis will lease
the property for 20 years, with two 10-year options to renew and a
right of first offer to purchase the property.
"From our inception, Ionis has been committed to discovering and
developing transformational medicines for patients who depend on
us. Our new Oceanside campus will
provide the capacity we need to support our growing pipeline, new
technologies and chemistries," said Brett
P. Monia, Ph.D., Ionis' chief executive officer. Dr. Monia
added, "We're proud to have established and grown our business in
North County, San Diego over the
last 30 years and delighted that we will continue to grow here for
decades to come."
The new facility will include advanced sustainability and
environmental protection features such as generating 50% of its
power from solar panels and renewable offset, increased automation
to reduce manual material handling, emissions controls and spill
containment for all production areas. Ionis expects to occupy the
new facility in 2025, with active pharmaceutical ingredient ("API")
manufacturing beginning in mid-2026. At approximately 217,000
square feet, the new facility will be more than double the size of
Ionis' existing development chemistry and manufacturing facility,
which is in Carlsbad.
Sudberry Properties is a San
Diego-based real estate development and asset management
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in
RNA-targeted therapy, pioneering new markets and changing standards
of care with its novel antisense technology. Ionis currently has
three marketed medicines and a premier late-stage pipeline
highlighted by industry-leading cardiovascular and neurological
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision of
becoming a leading, fully integrated biotechnology company.
To learn more about Ionis, visit www.ionispharma.com and follow
us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding
Ionis' business and the therapeutic and commercial potential of
Ionis' technologies. Any statement describing Ionis' goals,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, including but not limited to those related to our
commercial products and the medicines in our pipeline, and
particularly those inherent in the process of discovering,
developing and commercializing medicines that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such medicines. Ionis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good
faith judgment of its management, these statements are based only
on facts and factors currently known by Ionis. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Ionis' programs are described in
additional detail in Ionis' annual report on Form 10-K for the year
ended Dec. 31, 2021, and the most
recent Form 10-Q quarterly filing, which are on file with the
Securities and Exchange Commission. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals,
View original content to download
SOURCE Ionis Pharmaceuticals, Inc.